Femasys, Inc. (FEMY)
NASDAQ:FEMY
Want to see FEMY full AI Analyst Report?
FEMY Stock Chart & Stats
$0.73
-$0.01(-0.91%)
At close: 4:00 PM EST
$0.73
-$0.01(-0.91%)
Day’s Range― - ―
52-Week Range$4.02 - $22.22
Previous CloseN/A
Volume25.00K
Average Volume (3M)92.95K
Market Cap
$12.62M
Enterprise Value$10.74M
Total Cash (Recent Filing)$5.39M
Total Debt (Recent Filing)$4.73M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Aug 12, 2026EPS Estimate
-1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.43
Shares Outstanding3,019,534
10 Day Avg. Volume76,703
30 Day Avg. Volume92,954
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.88
Price to Sales (P/S)9.93
P/FCF Ratio-1.19
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue4.52
Enterprise Value/Gross Profit8.50
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$30.00Price Target Upside4009.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.53
Revenue Forecast (FY)$3.77M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Commercial TractionMulti-year revenue growth demonstrates improving product adoption and expanding clinical traction for FemVue and related consumables. Sustained top-line momentum from a small base indicates the company is beginning to commercialize its portfolio, which supports long-term revenue scaling if adoption and reimbursement continue.
Healthy Gross MarginsConsistently strong gross margins imply favorable unit economics for Femasys’s device and consumable offerings. Healthy product margins provide room to invest in sales and regulatory activities while preserving upside to eventual operating leverage as revenue scales and fixed costs are spread over larger volumes.
Experienced Operational LeadershipHiring a seasoned medical-device operations executive strengthens the company's ability to scale manufacturing, quality systems, and global commercialization. Durable operational leadership reduces execution risk during commercialization and supports scalable supply chain and regulatory processes over the medium term.
Bears Say
Severe Cash BurnLarge, persistent negative operating and free cash flow indicate the business is not yet self-funding and will require additional capital to sustain operations. Continued cash burn constrains strategic flexibility, increases reliance on external financing, and can pressure execution timelines if funding terms deteriorate.
Very Deep Operating And Net LossesExtremely negative margins reflect a cost structure far outpacing current revenue, signaling the business has not achieved scalable profitability. Absent substantial revenue expansion or structural cost reductions, these losses will continue to depress returns and complicate prospects for sustainable shareholder value creation.
Financing Dependence And Dilution RiskShareholder approval to issue large incremental equity on conversion/exercise and recent warrant issuances underline reliance on financings. This creates durable dilution risk, potential governance influence by lenders, and constrains capital structure flexibility as the company scales commercialization.
Femasys News
FEMY FAQ
What was Femasys, Inc.’s price range in the past 12 months?
Femasys, Inc. lowest stock price was $4.02 and its highest was $22.22 in the past 12 months.
What is Femasys, Inc.’s market cap?
Femasys, Inc.’s market cap is $12.62M.
When is Femasys, Inc.’s upcoming earnings report date?
Femasys, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 59 days.
How were Femasys, Inc.’s earnings last quarter?
Currently, no data Available
Is Femasys, Inc. overvalued?
According to Wall Street analysts Femasys, Inc.’s price is currently Undervalued.
Does Femasys, Inc. pay dividends?
Femasys, Inc. does not currently pay dividends.
What is Femasys, Inc.’s EPS estimate?
Femasys, Inc.’s EPS estimate is -1.27.
How many shares outstanding does Femasys, Inc. have?
Femasys, Inc. has 3,019,534 shares outstanding.
What happened to Femasys, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Femasys, Inc.?
Currently, no hedge funds are holding shares in FEMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Femasys, Inc.
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
FEMY Stock 12 Month Forecast
Average Price Target
$30.00
▲(4009.59% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
NexGel Inc
―
―
Ownership Overview
2.83% Insiders
2.62% Mutual Funds
11.06% Other Institutional Investors
81.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---